Proteins are the most advanced nanotechnology we know of, and Adaptyv is betting that a next-gen foundry can turn them into a routine engineering material. The company has raised $40.1M in a Series A round to scale up that vision.
Adaptyv Bio builds a platform that lets researchers synthesize and test any protein they design, effectively industrializing the process of moving from a digital blueprint to a physical, validated molecule. The fresh capital will go toward expanding that foundry's capacity and capabilities, though the company hasn't disclosed who's backing the round. What's clear is the ambition: making protein design as accessible as writing code.
